Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

BACKGROUND: Mean survival in cancer trials can be estimated with statistical techniques to extrapolate study survival curves. This methodology was applied to data from the VELOUR trial, where use of the novel biologic aflibercept (ziv-aflibercept in the United States) in combination with fluorouraci...

Descripción completa

Detalles Bibliográficos
Autores principales: Joulain, F, Proskorovsky, I, Allegra, C, Tabernero, J, Hoyle, M, Iqbal, S U, Van Cutsem, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790175/
https://www.ncbi.nlm.nih.gov/pubmed/24045663
http://dx.doi.org/10.1038/bjc.2013.523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790175/
https://www.ncbi.nlm.nih.gov/pubmed/24045663
http://dx.doi.org/10.1038/bjc.2013.523

Ejemplares similares